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Open Forum Infectious Diseases
Characteristics of Nontuberculous Mycobacterial 
Infections at a Midwestern Tertiary Hospital: 
A Retrospective Study of 365 Patients
Claire E. Hannah,1,  Bradley A. Ford,2 Jina Chung,3 Dilek Ince,4 and Karolyn A. Wanat,5 
1Department of Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA, 2Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, 
USA, 3Department of Dermatology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA, 4Department of Internal Medicine, Division of Infectious Diseases, University of Iowa Hospitals 
and Clinics, Iowa City, Iowa, USA, 5Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Background. The prevalence of infections due to nontuberculous mycobacteria (NTM) is increasing worldwide, yet little is 
known about the epidemiology and pathophysiology of these ubiquitous environmental organisms. Pulmonary disease due to 
Mycobacterium avium complex is most prevalent, but many other NTM species can cause disease in virtually any organ system. As 
NTM becomes an increasingly common cause of morbidity and mortality, more information is needed about the epidemiology of 
NTM disease.
Methods. We conducted a retrospective chart review of all patients with cultures that grew NTM at a Midwestern tertiary hos-
pital from 1996 to 2017. Information on demographics, medical history, clinical findings, treatment, and outcome was obtained from 
medical records of all NTM isolates. American Thoracic Society/Infectious Diseases Society of America criteria were used to define 
pulmonary NTM infections.
Results. We identified 1064 NTM isolates, 365 of which met criteria for NTM infection. Pulmonary cases predominated (185 of 
365; 50.7%), followed by skin/soft tissue (56 of 365; 15.3%), disseminated (40 of 365; 11%), and lymphatic (28 of 365; 7.7%) disease. 
Mycobacterium avium complex was the most common species (184 of 365; 50.4%). Individuals aged >50 years were most affected 
(207 of 365; 56.7%). Common comorbidities included structural lung disease (116 of 365; 31.8%), use of immunosuppressive medi-
cations (78 of 365; 21.4%), malignancy (59 of 365; 16.2%), and human immunodeficiency virus (42 of 365; 11.5%).
Conclusions. This large cohort provides information on the demographics, risk factors, and disease course of patients with 
pulmonary and extrapulmonary NTM infections. Most patients had medical comorbidities that resulted in anatomic, genetic, or 
immunologic risk factors for NTM infection. Further population-based studies and increased disease surveillance are warranted to 
further characterize NTM infection prevalence and trends.
Keywords.  atypical mycobacteria; nontuberculous mycobacteria.
Nontuberculous mycobacteria (NTM), generally defined as 
mycobacteria not in the Mycobacterium tuberculosis complex 
(MTC) and other than Mycobacterium leprae, represent a di-
verse and emerging group of pathogens that cause disease in 
both immunocompromised and immunocompetent people [1]. 
Nontuberculous mycobacteria are ubiquitous in the environ-
ment and are thought to be acquired through exposure to water, 
soil, animals, plants, and food sources [2, 3]. Nontuberculous 
mycobacteria infections can involve any organ system but most 
commonly manifest as pulmonary disease, skin/soft tissue in-
fection (SSTI), and lymphadenitis [1]. Higher rates of infection 
are seen in patients with underlying anatomic/structural organ 
abnormalities (eg, cystic fibrosis, bronchiectasis, emphysema) 
or immunodeficiency (eg, human immunodeficiency virus 
[HIV], organ transplant, immunosuppressive medications) [2, 
3]. Often, NTM infections present insidiously and mimic other 
conditions, resulting in delayed diagnosis and significant mor-
bidity and mortality [4]. Treatment methods and success rates 
vary depending on the organism and disease site.
The incidence of NTM infection is likely increasing at a steep 
rate [5]. Brode et al [6] found that although rates of tubercu-
losis are declining in many countries, infection and death from 
NTM are rising. In the 1980s, NTM disease prevalence was re-
ported at 1.6 to 1.8 per 100 000 people, whereas recent studies 
have shown a prevalence of 14.1 per 100 000 in North America 
[4]. These infections disproportionately affect the elderly, sug-
gesting that NTM disease will become even more common 
as the population ages [4]. With increasing NTM-related 
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morbidity and mortality worldwide, more epidemiologic in-
formation is needed to guide diagnosis and management. In the 
United States, population-based data are lacking, partly because 
NTM are not reportable to public health authorities [7]. Much 
of the available data comes from laboratory-based surveillance, 
which does not provide the clinical or radiographic informa-
tion needed to distinguish true infection from colonization or 
contamination. In this study, thorough medical record review 
was performed on all patients with NTM culture isolates at a 
Midwestern tertiary hospital from 1996 to 2017. We collected 
clinical, radiographic, and microbiologic data from medical 
records to identify cases of true NTM infection and further 
characterize patient demographics, clinical manifestations, 




We conducted a retrospective medical record review of all pa-
tients with at least 1 positive NTM culture at the University of 
Iowa Hospitals and Clinics in Iowa City, Iowa between January 
1, 1996 and May 31, 2017. Patients of all ages were eligible 
for inclusion. Complete paper records of final, definitive iden-
tifications for all positive mycobacterial cultures were kept 
through the study period and were used to identify patients 
for chart review. All chart review data were obtained from hos-
pital electronic health records. The study was approved by the 
hospital’s institutional review board. During the period cov-
ered by this review, the number of hospital beds stayed essen-
tially the same at approximately 820, but the number of clinics 
expanded from approximately 30 to 300. The University of 
Iowa serves a population of several million as the only aca-
demic institution in the state.
Laboratory Methods
Samples were decontaminated with reagents created by an 
in-house reagent laboratory, and primary samples and pos-
itive cultures were stained with both Auramine-Rhodamine 
and Ziehl-Neelsen. Blood cultures were collected in BACTEC 
12B/13A bottles, BACTEC MYCO/F Lytic bottles, or (rarely) 
Isolator tubes transferred to primary media (Lowenstein-Jensen 
and 7H10 or 7H11 media). Other broth cultures were per-
formed on the BACTEC MGIT 960 system. Sterile material was 
ground and transferred to these solid media. Solid media were 
incubated at 37°C in 5%–10% CO2. Skin, connective tissue, 
joint, and bone specimens were also incubated at 30°C, with an 
X-factor disk included to recover Mycobacterium haemophilum. 
Standard incubation was for  ≥6 weeks; positive acid-fast ba-
cillus smears that were culture negative at 6 weeks were held 
for an additional 4 weeks, and if Mycobacterium ulcerans was 
suspected, cultures were incubated for 8 weeks. Mycobacterium 
xenopi, which grows only slightly faster at 42°C versus 37°C, is 
recovered similarly to Mycobacterium avium complex (MAC) 
under these conditions [8], so primary culture at higher tem-
perature was not performed. Review of archived laboratory 
procedures reveals minor changes in culture technique over 
the study period that would not be expected to affect diag-
nostic yield or identification of NTM significantly. After 2014, 
bone marrow cultures were additionally incubated in BACTEC 
MYCO/F Lytic bottles. After 2013, the institution transitioned 
from cotton swabs, from which mycobacteria were essentially 
never recovered, to Copan eSwabs, from which mycobacteria 
are rarely recovered. Throughout the study period, laboratory 
policy was that tissue or fluid should be pursued over swabs as 
the preferred diagnostic sample.
The AccuProbe system was used to identify M tuberculosis 
to complex level, M avium/intracellulare to complex level, and 
Mycobacterium gordonae (after 2006). If isolates were initially 
probe-positive for MTC and Mycobacterium bovis infection 
was suspected, further identification was made by biochemical 
or genetic methods. After 2014, some MAC isolates were fur-
ther identified as Mycobacterium chimaera using whole genome 
sequencing at National Jewish Hospital. Otherwise, MTC and 
MAC were not routinely identified to the species level. After 
probes were performed, rapidly growing mycobacteria were 
identified to group level by 3-day arylsulfatase and standard-
ized growth studies. Subsequently, definitive identification was 
performed by sending samples to ARUP Laboratories for iden-
tification of slow-growers other than MTC, the State Hygienic 
Laboratory at the University of Iowa and the Centers for Disease 
Control and Prevention for MTC with susceptibility testing, 
and the University of Texas Health Science Center at Tyler for 
identification of rapidly growing NTM by gene sequencing.
Data Collection
Review of the electronic medical record was performed on all 
patients with at least 1 NTM culture isolate, as well as on patients 
whose cultures grew M bovis. Although M bovis is a subspecies 
of the MTC, an exception was made to include these cases in 
the study because they were clinically significant, iatrogenic 
infections from use of intravesical bacillus Calmette-Guerin 
(BCG) for the treatment of bladder cancer. After detailed chart 
review, cases were excluded from primary data analysis for 1 
of 3 reasons: (1) insufficient information in the medical record 
to diagnose infection (ie, limited/absent documentation of co-
morbid conditions, clinical presentation, treatment, or outcome 
of NTM infection), (2) NTM culture isolate identified as a con-
taminant (defined as a single positive culture without clinical or 
radiographic evidence of disease), or (3) NTM culture isolate 
represented colonization (defined as repeat positive cultures 
from the same specimen site without associated clinical or ra-
diographic evidence of disease). All M gordonae isolates were 
considered contaminants and excluded, because M gordonae is 
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the least pathogenic mycobacterial species and a frequent spec-
imen contaminant in the hospital environment [9]. For patients 
who had multiple NTM culture isolates from the same illness 
episode, only the first isolate was included in data analysis.
Information collected during chart review included patient 
demographics, relevant comorbid medical conditions (eg, HIV, 
chronic lung disease, malignancy, transplant recipient), relevant 
exposures (eg, recent travel, drug or tobacco use, recent health-
care interventions), and chronic medications, specifically fo-
cusing on immunosuppressive medications defined as systemic 
corticosteroids at doses equivalent to ≥15 mg/day prednisone 
for  ≥1 month, tumor necrosis factor inhibitors, and a variety 
of non-corticosteroid immunosuppressive agents including 
immunophilin-binding drugs, antimetabolites, and alkylating 
agents. We collected information on the clinical presentation 
and longitudinal course of NTM infection, microbiologic data, 
and any available laboratory, radiographic, and histopathologic 
data. Finally, all available notes were reviewed to determine 
the treatment regimen and clinical outcome for each patient. 
Clinical outcomes were grouped into 3 categories based on 
the most recent information in the medical record at the end 
of the study period: resolution of infection, chronic/persistent 
infection, and death. Cause of death was most commonly de-
termined by clinical judgment of the primary medical team or 
expert consultants caring for the patient at the time of death, as 
documented in the medical record. In 4 cases, autopsy records 
were available to determine cause of death.
Pulmonary Nontuberculous Mycobacteria Infection Definition
Cases of pulmonary NTM infection were diagnosed using 
the American Thoracic Society/Infectious Diseases Society of 
America (ATS/IDSA) diagnostic criteria [9], which require 
clinical symptoms and signs of disease, radiographic evidence 
of disease, and mycobacterial cultures to formulate diagnostic 
criteria NTM lung disease. Clinical and microbiologic criteria 
consist of positive culture results from ≥2 separate expector-
ated sputum samples or  ≥1 bronchial wash or lavage. A single 
investigator collected data from the medical record, reviewed 
documentation by the patient’s primary team and/or expert con-
sultants (eg, pulmonology, infectious diseases), and synthesized 
this information to identify cases of pulmonary NTM infection 
according to ATS/IDSA guidelines.
Extrapulmonary Nontuberculous Mycobacteria Infection Definition
We defined extrapulmonary infection as  ≥1 positive culture 
from an ordinarily sterile site with associated clinical evidence of 
disease. Categories of extrapulmonary NTM infection included 
SSTI, lymphadenitis, isolated bacteremia, ocular, sinus, geni-
tourinary, gastrointestinal, intraperitoneal, intraarticular, and 
bone infections, as well as disseminated disease. Classification 
into a given category meant that all available microbiologic and 
clinical information indicated that infection was limited to that 
single organ system. Disseminated disease was defined as clin-
ical, microbiologic, and/or radiographic evidence of NTM in-
fection in at least 2 nonadjacent organ systems.
Data Analysis
Descriptive statistics were used to examine the frequency and 
distribution of variables of interest. Multivariable logistic re-
gression analyses were performed to assess for factors associated 
with disseminated mycobacterial infection and mortality from 
mycobacterial infection. We reached our final model using a 
backwards elimination approach, retaining predetermined po-
tential confounders (age and gender) and significant covariates 
(P < .05 on the Wald test). Model fit was assessed using the 
Hosmer-Lemeshow goodness-of-fit test. All statistical analyses 
were performed using STATA 14 (STATA Corporation, College 
Station, TX).
RESULTS
Between 1996 and 2017, the hospital laboratory identified 1064 
positive NTM cultures, of which 139 were contaminants, 152 
represented colonization, 337 were repeat positive cultures 
from the same patient and illness, and 71 lacked sufficient in-
formation in the medical record to determine whether infection 
was present (Figure 1). After exclusions, a total of 365 cases met 
criteria for infection.
The age of patients meeting disease criteria (n = 365) ranged 
from 1 to 95 years, with a median age of 55 years. Approximately 
half (193 of 365; 52.9%) were female. Three hundred twenty-two 
(88.2%) of the 365 patients were white, 15 (4.1%) were black, 10 
(2.7%) were Hispanic, and 6 (1.6%) were Asian. Pulmonary dis-
ease predominated (185 of 365; 50.7%), followed by SSTI (56 of 
365; 15.3%), disseminated disease (40 of 365; 11.0%), and lym-
phadenitis (28 of 365; 7.7%) (Table 1). Mycobacterium tubercu-
losis complex was the most common NTM isolate (184 of 365; 
50.4%), followed by Mycobacterium chelonae (54 of 365; 14.8%), 
Mycobacterium kansasii (21 of 365; 5.8%), Mycobacterium 
abscessus (20 of 365; 5.5%), and Mycobacterium fortuitum (19 of 
365; 5.2%). Females were disproportionately affected by MAC 
(106 of 184; 57.6%) and M abscessus (14 of 20; 70%), whereas 
males were more commonly affected by M kansasii (15 of 
21; 71.4%).
Overall, 60 (60 of 365; 16.4%) patients died during the study 
period, and NTM infection was considered the primary cause 
of death in 63.3% (38 of 60) of cases. The majority of deaths 
from NTM resulted from pulmonary and disseminated in-
fections, with case-fatality rates of 10.8% and 50% during the 
study period, respectively (Table  2). Patients who deceased 
from mycobacterial infection were compared with patients 
with NTM infection who deceased from other causes, re-
covered from infection, or remained stable with chronic in-
fection. Patients whose outcomes were unknown (n = 50) 
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were excluded from analysis. The factors associated with 
significantly increased odds of mortality from mycobacterial 
infection were as follows: disseminated mycobacterial infec-
tion (odds ratio [OR], 5.0; 95% confidence interval [CI], 1.6–
15.0; P = .005), concomitant HIV infection (OR, 5.5; 95% CI, 
1.4–21.6; P = .014), history of immunosuppressive therapy 
(OR, 4.9; 95% CI, 1.9–12.9; P = .001), and history of uninten-
tional weight loss at presentation (OR, 4.0; 95% CI, 1.5–10.4; 
P = .005).
Pulmonary Disease
Pulmonary disease accounted for 50.7% (185 of 365) of infec-
tions, the majority of which were caused by MAC (127 of 185; 
68.6%), then M kansasii (15 of 185; 8.1%) and M abscessus (14 of 
185; 7.6%). Demographics of patients with pulmonary disease 
were similar to the overall study population (Table  2). Sixty-
percent (112 of 185; 60.5%) of patients with pulmonary NTM 
infection had underlying structural lung disease, including 56 
(56 of 185; 30.3%) with chronic obstructive pulmonary disease, 
49 (49 of 185; 26.5%) with bronchiectasis, 14 (14 of 185; 7.6%) 
with cystic fibrosis, 11 (11 of 185; 5.9%) with interstitial lung 
disease, and 5 (5 of 185; 2.7%) with history of lung transplant. 
The majority (101 of 185; 54.6%) of patients with pulmonary 
disease were cigarette smokers, and 18.4% (34 of 185)  were 
taking ≥1 immunosuppressive medication at the time of diag-
nosis. When looking specifically at cases of MAC pulmonary 
disease (MAC-PD) (n = 127), women were more commonly 
affected (76 of 127; 59.8%). Less than half (35 of 76; 46.1%) 
Positive mycobacteria cultures
























Excluded (n = 135)
Excluded (n = 139)
Excluded (n = 337)
Excluded (n = 71) 
Excluded (n = 152)
Figure 1. Flowchart of patient selection. A logging system containing the medical record numbers of all patients between 1996 and 2017 at the University of Iowa Hospitals 
and Clinics with cultures positive for Mycobacterium tuberculous or nontuberculous mycobacteria (NTM) was reviewed. Medical record review was performed on all patients 
with cultures positive for NTM or Mycobacterium bovis. Infection was defined using the American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) NTM 
lung disease guidelines. Contaminant was defined as a single positive culture without clinical or radiographic evidence of disease. Colonization was defined as ≥2 positive 
cultures without clinical or radiographic evidence of disease. Cases were excluded if medical records lacked sufficient information to diagnose infection according to ATS/
IDSA guidelines. Cases of chronic NTM infection with multiple positive cultures were included only once in data analysis.
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of women with MAC-PD smoked cigarettes, compared with 
68.6% (35 of 51) of men with MAC-PD.
The most common initial manifestations of pulmonary NTM 
infection were cough, hemoptysis, weight loss, and fever. The 
most common radiographic findings in patients with pulmo-
nary NTM infection were fibrocavitary disease (observed in 
52 patients), nodular/bronchiectatic disease (observed in 48 
patients), and dense consolidation or solitary, noncavitating 
mass (observed in 23 patients). Multifocal bronchiectasis alone 
was observed in 33 patients with pulmonary NTM infection, 
but the chronicity of radiographic bronchiectasis and whether 
it preceded the diagnosis of NTM infection could not always 
be determined. In women with MAC-PD (n = 76), nodular/
bronchiectatic radiographic findings were observed 50 patients, 
and fibrocavitary changes were observed in 19 patients. For men 
with MAC-PD (n = 51), 27 patients had nodular/bronchiectatic 
radiographic findings, and 15 had fibrocavitary changes.
Of the patients who received medical treatment (117 of 
185; 63.2%), antibiotic regimens typically included macro-
lide antibiotics (98 of 117; 83.8%), ethambutol (101 of 117; 
86.3%), and rifamycin antibiotics (93 of 117; 79.5%). The ma-
jority (80 of 117; 68.4%) of patients who received treatment 
were on anti-mycobacterial medications for  ≥12  months, 
with 1 patient on treatment for 11 years. Approximately one 
third (60 of 185, 32.4%) of patients with pulmonary NTM had 
full resolution of infection, 32.4% (60 of 185) had chronic in-
fection, and 18.9% (35 of 185) died. Of the 35 patients who 
died, NTM was identified as the underlying cause of death in 
57.1% (20 of 35) of cases.
Skin/Soft Tissue Infection
There were 56 (56 of 365; 15.3%) SSTIs, the majority (33 of 56; 
58.9%) of which occurred in females. Mycobacterium chelonae 
was the most common organism (19 of 56; 33.9%), followed by 
M fortuitum (10 of 56; 17.9%) and Mycobacterium marinum (8 
of 56; 14.3%). Approximately half (29 of 56; 51.8%) of SSTIs oc-
curred after documented injury to the skin. Fourteen SSTIs (14 
of 56; 25%) were iatrogenic infections and occurred at the site of 
injections, lines and catheters, surgical wounds, or medical im-
plants. There were 15 cases of nonhealthcare-associated trauma 
preceding SSTI, including gardening injuries, chemical burns, 
intravenous drug use, tattoos, pedicures, and injuries while 
cleaning fish tanks. Three of the 15 cases of nonhealthcare-
associated trauma involved self-inflicted injuries in patients 
who were diagnosed with factitious disorder imposed on self 
(ie, Munchausen syndrome). In all 3 cases, patients presented 
with recurrent, nonhealing SSTIs that were eventually attrib-
uted to self-injection of foreign substances including feces and 
pond water.
The clinical manifestations of SSTIs were varied and in-
cluded papules, plaques, nodules, abscesses, cellulitis, ulcers, 
panniculitis, and 1 case of necrotizing fasciitis. The majority 
(30 of 56; 53.6%) of SSTIs involved the upper extremities, 15 
(15 of 56; 26.8%) involved the trunk, and 11 (11 of 56; 19.6%) 
involved the lower extremities. Thirty-five (35 of 56; 62.5%) pa-
tients required surgical intervention to achieve disease resolu-
tion, ranging from simple surgical excision to limb amputation. 
Full disease resolution was achieved in 83.9% (47 of 56) of cases. 
One patient with a severe M abscessus SSTI at the exitsite of a 
Table 1. Frequency of Nontuberculous Mycobacteria Species by Disease Site
Organism Pulmonary SSTI Lymphatic Disseminated Othera Total
Mycobacterium avium complex 127 2 26 25 4 184 (50)
 Mycobacterium chimaerab    4  4 (1)
Mycobacterium chelonae 10 19  2 23 54 (15)
Mycobacterium kansasii 15 5   1 21 (6)
Mycobacterium abscessus 14 3  1 2 20 (5)
Mycobacterium fortuitum 4 10   5 19 (5)
Mycobacterium bovis    2 7 9 (2)
Mycobacterium marinum  8   1 9 (2)
Mycobacterium xenopi 4 1 1  0 6 (2)
Mycobacterium mucogenicum  2   4 6 (2)
Mycobacterium NOS 5 2  2 6 15 (4)
Combinationc 5   4 1 10 (3)
Otherd 1 4 1  2 8 (2)
Total 185 (51) 56 (15) 28 (8) 40 (11) 56 (15) 365
Abbreviations: SSTI, skin/soft tissue infection; NOS, not otherwise specified.
NOTE: Values represent number of cases (%). 
aIncludes ocular (n = 19), bacteremia (n = 15), sinus (n = 4), genitourinary (n = 6), intraperitoneal (n = 4), intraarticular (n = 4), bone (n = 2), and gastrointestinal (n = 2).
bMycobacterium chimaera is a member of the M avium complex but was separated for clarity.
cIncludes M avium complex/M chelonae (n = 6), M avium complex/M kansasii (n = 1), M chelonae/M abscessus (n = 1), M fortuitum/M kansasii (n = 1), and M mucogenicum/Mycobacterium 
phocaicum (n = 1).
dIncludes Mycobacterium neoaurum (n = 2), Mycobacterium terrae complex (n = 2), Mycobacterium obuense (n = 1), Mycobacterium porcinum (n = 1), Mycobacterium scrofulaceum 
(n = 1), and Mycobacterium smegmatis (n = 1).
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percutaneous gastrostomy tube died from septic shock attrib-
uted to NTM infection.
Disseminated Disease
Of the 365 patients diagnosed with NTM infection, 40 (11.0%) 
had disseminated infection. Mycobacterium avium complex 
was identified in 25 of the 40 cases (62.5%), and an additional 
4 patients with disseminated infection had cultures growing a 
combination of MAC and M chelonae. Cultures were obtained 
from a variety of sources, including bone marrow, stool, cere-
brospinal fluid, peritoneal fluid, prostate tissue, abscesses, and 
blood. The factors associated with significantly increased odds 
of disseminated mycobacterial infection were HIV infection 
(OR, 32.8; 95% CI, 12.8–84.2; P < .001) and having a history 
of night sweats at presentation (OR, 4.3; 95% CI, 1.6–12.0; 
P = .005). The presenting signs and symptoms of disseminated 
disease most commonly included fever (25 of 40; 62.5%), weight 
loss (14 of 40; 35%), and night sweats (13 of 40; 32.5%). Eleven 
patients with disseminated NTM had pulmonary involvement 
of disease; only 1 of these patients had fibrocavitary lung disease 
on imaging, whereas the rest had a multifocal, reticulonodular 
pattern.
Ninety-percent (36 of 40) of disseminated NTM infection de-
veloped in severely immunocompromised patients, including 
26 (26 of 40; 65%) patients with HIV, all of whom had MAC 
infection. For all 42 patients in this study with HIV, the median 








Age (Years)    
 Median 63 42 44
 Range 3–95 1–87 1–88
Gender    
 Female 101 (55) 13 (33) 79 (56)
 Male 84 (45) 27 (68) 61 (44)
Race    
 White 168 (91) 31 (78) 123 (88)
 Black 4 (2) 7 (18) 4 (3)
 Hispanic 3 (2) 1 (3) 6 (4)
 Asian 6 (3) 0 0
Comorbidities    
 Structural lung diseaseb 112 (61) 0 4 (3)
 Solid malignancy 36 (19) 7 (18) 16 (11)
 Hematologic malignancy 12 (6) 9 (23) 15 (11)
 Solid organ transplant 8 (4) 2 (5) 4 (3)
 Hematopoietic stem cell transplant 6 (3) 1 (3) 4 (3)
 HIV 15 (8) 26 (65) 1 (1)
 Iatrogenicc 1 (1) 9 (23) 50 (34)
 Severe neutropeniad 2 (1) 5 (13) 3 (2)
Risk factors    
 Current smoker 101 (55) 20 (50) 34 (24)
 Immunosuppressive medicatione 34 (18) 6 (15) 38 (27)
 IV drug use 6 (3) 5 (13) 5 (4)
Treatmentf    
 Medical 129 (70) 28 (70) 89 (64)
 Surgical 13 (7) 5 (13) 92 (66)
Outcome    
 Resolved 60 (32) 8 (20) 120 (86)
 Persistent infection 60 (32) 3 (8) 4 (3)
 Deceased from NTM 20 (11) 20 (50) 3 (2)
Abbreviations: HIV, human immunodeficiency virus; IV, intervenous; NTM, nontuberculous mycobacteria.
NOTE: Values represent number of patients (%). 
aNondisseminated, extrapulmonary infections. 
bChronic obstructive pulmonary disease, bronchiectasis, cystic fibrosis, interstitial lung disease. 
cInfections directly related to diagnostic and therapeutic procedures performed on the patient. 
dAbsolute neutrophil count ≤500 cells/mm3. 
eSystemic corticosteroids at doses equivalent to  ≥15  mg/day prednisone ≥1  month, tumor necrosis factor inhibitors, and noncorticosteroid immunosuppressive agents including 
immunophilin-binding drugs, antimetabolites, and alkylating agents.
fIndicates whether patients’ treatment course included antimicrobial therapy or surgical intervention. Patients could be included in more than 1 category.
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CD4 count at the time of NTM infection diagnosis was 23 cells/
mm3 (interquartile range, 6–69). Other comorbidities in pa-
tients with disseminated infection included idiopathic CD4 
lymphopenia, Mendelian susceptibility to mycobacterial dis-
eases, acute leukemia, and severe neutropenia, defined as ab-
solute neutrophil count <500 cells/mm3. As previously reported 
by Marra et al [10], there were 4 cases of disseminated infection 
caused by M chimaera, a MAC subspecies, in patients who had 
been exposed to contaminated heater-cooler units used during 
cardiothoracic surgery. There were 2 cases of disseminated in-
fection from M bovis after intravesical BCG therapy for bladder 
cancer.
Lymphadenitis
There were 28 cases of NTM lymphadenitis, and the majority 
(26 of 28; 92.9%) of patients were  ≤6  years of age. Twenty 
(71.4%) of the 28 patients were female. Only 2 adult patients 
were diagnosed with isolated lymphadenitis, both of whom 
were severely immunocompromised. Twenty-six (92.9%) of 
the 28 cases were caused by MAC; the remaining 2 cases were 
caused by Mycobacterium scrofulaceum and M xenopi. All pa-
tients presented with a progressively enlarging head/neck mass, 
often with overlying erythematous skin changes. Swelling was 
painless in 24 of 28 cases. Fever was reported in only 2 patients. 
All cases of lymphadenitis occurred in the head/neck region 
and involved either cervical (16 of 28; 57.1%), submandibular 
(7 of 28; 25.0%), or preauricular (5 of 28; 17.9%) lymph nodes. 
All patients required surgical excision of the infected node, and 
8 (8 of 28; 28.6%) received adjuvant anti-mycobacterial therapy; 
the median duration of therapy in these patients was 2 months. 
All cases of lymphadenitis fully resolved with treatment.
DISCUSSION
This study represents one of the largest retrospective chart re-
views on NTM infections in a cohort of patients diagnosed at a 
Midwestern facility over the course of 2 decades. By reviewing 
medical records, we were able to correlate NTM cultures with 
clinical and radiographic data to identify clinically significant 
NTM infection using the ATS/IDSA diagnostic criteria [11].
The findings in this study were consistent with US NTM dis-
ease patterns reported in the literature, particularly regarding 
patient demographics, risk factors, organism, and organ in-
volvement. We identified MAC as the most common organism 
and pulmonary disease as the most common site of infection. 
These findings reflect the fact that MAC-PD is the most preva-
lent NTM infection worldwide [7, 11, 12, 13]. The prevalence of 
MAC compared with other NTM species is not completely un-
derstood but may be a result of its ability to form biofilms, high 
innate chlorine and biocide resistance, and tolerance of extraor-
dinarily low nutrient levels and temperature extremes. These 
features allow MAC to persist in both treated and untreated 
water sources, which then presumably leads to human expo-
sure through drinking, bathing, and swimming [14]. There are 
2 prototypical phenotypes for MAC-PD: (1) slowly progressive 
nodular bronchiectatic disease in postmenopausal, nonsmoking 
females (“Lady Windermere syndrome”) [15] and (2) rapidly 
progressive fibrocavitary disease in older males with underlying 
smoking-related lung disease [16]. In accordance with these 
classic phenotypes, we found that MAC-PD was more common 
in women, the majority of whom were nonsmokers, whereas 
most men with MAC-PD were smokers. In this study popula-
tion, nodular/bronchiectatic changes were the most common 
radiographic finding in MAC-PD for both men and women.
After lung disease, we identified SSTIs as the most frequent 
manifestation of NTM infection. The incidence of cutaneous 
NTM appears to be increasing [17]. Although NTM SSTIs typ-
ically remain localized to the skin/soft tissues, they typically 
have a protracted clinical course requiring surgical interven-
tions and multidrug regimens. Similar to findings from a re-
cent retrospective case series on cutaneous NTM by Philips 
et al [18], we found that SSTIs were most commonly caused by 
rapid-growing NTM species (ie, M chelonae, M fortuitum), as 
well as the slow-grower M marinum. One significant finding 
from our cohort was that 1 in 4 SSTIs were considered nosoco-
mial infections. We also identified iatrogenic infections of the 
bloodstream, eye, urinary tract, joint, bone, and intraperitoneal 
space, as well as disseminated disease from M chimaera. 
Prevention of nosocomial NTM is challenging when so little 
is known on the mechanism of disease acquisition and path-
ophysiology [11]. Currently, water sources, particularly tap 
water, pose the greatest risk for healthcare-associated NTM in-
fections, particularly SSTIs. The use of hospital tap water during 
any sterile or nonsterile procedure should be avoided to prevent 
healthcare-associated NTM outbreaks [11].
The majority of patients in our cohort were >50  years old, 
reflecting the strong association between aging and NTM in-
fection [7, 12]. This association may be due to decreased ef-
ficiency of cell-mediated immunity, as well structural and 
functional changes in organ systems that occur with aging [19]. 
Regardless of the affected organ system, most patients in our 
cohort had pre-existing structural, immunologic, or genetic 
abnormalities that conferred increased risk for infection, such 
as structural lung disease in patients who acquired pulmonary 
infections, physical tissue trauma preceding the development 
of SSTIs, and patients with HIV who developed disseminated 
NTM. Increased prevalence of NTM infection in patients with 
predisposing factors is well documented in the literature [1]. 
Szymanski et al [20] suggested that even in otherwise healthy 
patients with NTM pulmonary disease, there are multiple un-
derlying genetic variants that may increase susceptibility to 
infection.
Although aging, medical comorbidities, and immunodefi-
ciencies are major risk factors for NTM infection, Al-Houqani 
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et al [21] demonstrated that these factors only partly account 
for the increasing prevalence of NTM disease. There are likely 
unknown environmental and/or pathogen-specific factors 
that are also contributing to increased disease prevalence. 
This concept is demonstrated in the epidemiology of NTM 
lymphatic infections. Mycobacterial lymphadenitis is a rela-
tively common pediatric infection that typically occurs in oth-
erwise healthy children. The prevailing theory is that children 
acquire NTM from drinking water and/or frequent hand-to-
mouth contact with NTM in soil [11, 22]. Historically, M 
scrofulaceum was the most common cause of NTM lymphad-
enitis in the United States until approximately 1975, when 
rates of M scrofulaceum sharply declined and MAC became 
the predominant cause of infection [14]. Primm et  al [14] 
proposed that this shift may have resulted from the imple-
mentation of the Clean Water Act in 1972, when increased 
use of chlorination of public water supplies allowed chlorine-
resistant NTM species (ie, MAC) to persist, whereas the more 
chloride-susceptible M scrofulaceum became less prevalent 
[14, 23]. This is reflected in our cohort, where almost all cases 
of lymphadenitis were caused by MAC and only 1 was from M 
scrofulaceum. Environmental and pathogen-specific factors 
may also explain the geographical differences in NTM spe-
cies worldwide [14]. Similar to other North American-based 
studies, we found that M chelonae, M kansasii, M abscessus, 
and M fortuitum were the most common causes of infection 
after MAC, whereas Mycobacterium malmoense, M xenopi, 
and M scrofulaceum predominate in other parts of the world 
[7, 11, 24]. In addition to worldwide differences in NTM spe-
cies, Spaulding et  al [24] demonstrated that there are likely 
differences in geographical distribution even within the 
United States. They found that MAC is more frequently iden-
tified in NTM isolates in the South and Northeast, whereas 
other regions, such as Iowa, have proportionally higher fre-
quencies of M abscessus/M chelonae isolates.
Limitations of this study are similar to the limitations of 
other epidemiologic studies of NTM and include lack of 
consensus on diagnostic criteria for extrapulmonary disease 
and microbiologic challenges with accurate identification 
and speciation of mycobacteria. Positive cultures for NTM 
must be interpreted with caution, with consideration of spec-
imen source and organism virulence. When synthesizing in-
formation from the medical records of patients with positive 
NTM cultures, it can be difficult to differentiate between 
cases of transient infection, true infection, colonization, and 
contamination, particularly in complex, systemically unwell 
patients with multiple medical comorbidities. Our findings 
were also limited by the retrospective nature of the study, 
the fact that data were collected from a single institution, 
and the fact that cases identified using nonculture methods 
(ie, polymerase chain reaction-based methods) were ex-
cluded from the study.
CONCLUSIONS
This retrospective chart review represents one of the lar-
gest reviews of clinical, radiographic, and microbiologic 
findings of NTM infections, providing a broad overview 
of the demographics and clinical manifestations of pul-
monary and extrapulmonary NTM infections and con-
tributing to the body of knowledge on this clinically 
significant yet poorly understood class of organisms. 
Nontuberculous mycobacteria infections pose a serious 
threat to patients and may risk development of antimicro-
bial resistance, particularly given that these diseases are 
notoriously challenging to recognize, diagnose, and treat 
in a timely manner, if at all [25]. Even within NTM disease 
states, (1) decisions to manage medically versus surgically 
and (2) antimicrobial therapeutic selections vary widely, 
making understanding the epidemiology of infection crit-
ical to improving patient outcomes. The most pressing 
issue in understanding NTM disease is the need for com-
prehensive surveillance efforts and systematic epidemio-
logic studies, which could be more readily performed if 
isolation of NTM or diagnosis of NTM disease were re-
portable to public health authorities, such as is required 
in the states of Oregon and Tennessee. In addition, further 
studies are needed to validate the use of the ATS/IDSA di-
agnostic criteria as well as to develop guidelines for the 
diagnosis and treatment of extrapulmonary infections.
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